依维莫司与舒尼替尼一线治疗转移性乳头状肾细胞癌:GETUG 回顾性研究
中位随访92个月,两组一线无进展生存期(5.5 vs 6.2个月)和疾病控制率(69% vs 83%)无显著差异。结论认为两种药物一线疗效相似。
要点
- 舒尼替尼与依维莫司一线治疗转移性乳头状肾细胞癌的PFS和DCR无显著差异。
- 二线治疗中,舒尼替尼后多用mTOR抑制剂,依维莫司后全部用TKI,疗效相似。
- 白细胞增多、贫血和诊断至首次系统治疗时间<1年为OS预后因素。
核心结论
- 舒尼替尼与依维莫司一线治疗转移性乳头状肾细胞癌疗效相似。
研究设计与样本
- 患者中位年龄62.5岁,男性119例、女性19例;1型24例、非1型114例。
- 一线接受舒尼替尼107例、依维莫司31例;主要终点为一线无进展生存期(PFS-1)。
主要发现
- 中位随访92个月,一线PFS-1为5.5个月(舒尼替尼)对6.2个月(依维莫司),无显著差异。
- 一线疾病控制率(DCR)为69%(舒尼替尼)对83%(依维莫司),无显著差异。
- 二线DCR为64%对58%,中位PFS-2为3.4对4.8个月,总生存期(OS)为16.0对20.3个月,均相似。
- 白细胞增多、贫血和诊断至首次系统治疗时间<1年为OS预后因素;IMDC风险因素对OS有预后价值。
临床怎么用
- 转移性乳头状肾细胞癌一线可考虑舒尼替尼或依维莫司,两者疗效相似。
- 二线治疗可根据一线用药选择换用mTOR抑制剂或TKI。
- OS预后可参考白细胞增多、贫血、诊断至治疗时间<1年及IMDC风险因素。
局限性
- 非随机对照,治疗选择可能存在偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Two phase II trials (NCT00688753 and NCT00541008) reported efficacy data of sunitinib and everolimus in first-line treatment of metastatic papillary renal cell carcinoma (mpRCC). Although most patients receive sunitinib or a mammalian target of rapamycin (mTOR) inhibitor in first- and second-line treatment, the optimal strategy remained unknown. MATERIAL AND METHODS: In 23 centres of the Groupe d'Etude des Tumeurs Urogénitales group, after centralised pathological review, we analysed retrospectively progression-free survival (PFS) of patients with mpRCC treated in first-line treatment (PFS-1) with sunitinib or everolimus (primary end-point), PFS in second-line treatment (PFS-2), overall survival (OS), objective response rate, disease control rate (DCR), overall sequence and prognostic factors for OS (secondary end-points). RESULTS: One hundred thirty-eight patients (119 men and 19 women), median age 62.5 years, with mpRCC type 1 (n = 24) or non-type 1 (n = 114), received first-line sunitinib (n = 107) or everolimus (n = 31). With a median follow-up of 92 months, we found no significant difference between the treatment groups in terms of PFS-1 (5.5 versus 6.2 months) and DCR (69% versus 83%). Ninety-eight patients received a second-line treatment, 69% with mTOR inhibitors after sunitinib and 100% with tyrosine kinase inhibitors after everolimus, with similar DCR (64% versus 58%), median PFS-2 (3.4 versus 4.8 months) and OS (16.0 versus 20.3 months). No factor was prognostic for PFS-1, whereas leukocytosis, anaemia and the time from diagnosis to first systemic therapy < 1 year were prognostic for OS. We found no prognostic difference between both pRCC subtypes. The International Metastatic Renal Cell Database Consortium risk factors were prognostic for OS. CONCLUSION: Sunitinib and everolimus had similar efficacy in first-line treatment of patients with mpRCC.
引用
- Cancel M, Fromont G, Blonz C, et al. Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales). Eur J Cancer. 2021. PMID: 34619467. doi:10.1016/j.ejca.2021.08.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。